Skip to main content

Table 4 Interaction between polymorphisms studied with saturated fat intake (≥12 g/d) and total fat (≥83 g/d)

From: Interaction of dietary fat intake with APOA2, APOA5 and LEPR polymorphisms and its relationship with obesity and dyslipidemia in young subjects

Variables

Obesity

Cholesterol

Triglycerides

LDL-C

HDL-C

IMC ≥ 30 kg/m2

≥200 mg/dL

≥150 mg/dL

≥100 mg/dL

≤40 mg/dL

OR (95 % CI); P a

SFA ≥ 12 g/d

3.9 (2.0–7.6); <0.001

1.8 (0.8–4.1); 0.15

1.3 (0.7–2.7); 0.4

1.5 (0.8–2.7); 0.2

1.0 (0.6–1.8); 0.9

Total fat ≥ 83 g/d

3.8 (1.9–7.7); <0.001

1.7 (0.7–3.9); 0.2

1.0 (0.5–2.2); 0.9

1.3 (0.7–2.4); 0.3

0.9 (0.5–1.8); 0.8

APOA5 gene

Polymorphism −1131 T/C

Genotype T/C + C/C

0.9 (0.5–1.7); 0.7

0.7 (0.3–1.7); 0.4

0.9 (0.4–2); 0.9

0.8 (0.4–1.4); 0.4

1.9 (1.0–3.6); 0.05

Interaction T/C + C/C – SFA (≥12 g/d)

1.4 (0.5–3.5); 0.5

0.5 (0.1–2.2); 0.3

1.4 (0.5–3.8); 0.5

1.0 (0.4–2.5); 0.9

2.1 (0.9–5.0); 0.09

Interaction T/C + C/C – Total fat (≥83 g/d)

0.9 (0.4–2.5); 0.9

0.5 (0.1–2.5); 0.4

1.2 (0.4–3.5); 0.7

1.0 (0.4–2.4); 1.0

1.9 (0.8–4.8); 0.13

Polymorphism 56 C/G

Genotype G/G

0.97 (0.5–1.8); 0.9

0.8 (0.4–1.8); 0.6

0.6 (0.3–1.2); 0.1

0.7 (0.4–1.3); 0.2

0.7 (0.4–1.2); 0.2

Interaction G/G – SFA (≥12 g/d)

2.7 (1.3–5.6); 0.006

0.97 (0.4–2.4); 0.9

1.2 (0.6–2.6); 0.6

0.8 (0.45–1.6); 0.6

0.8 (0.4–1.6); 0.5

Interaction G/G – Total fat (≥83 g/d)

2.4 (1.2–4.9); 0.018

1.1 (0.4–2.6); 0.9

1.0 (0.5–2.3); 0.9

0.7 (0.4–1.4); 0.4

0.8 (0.4–1.5);0.5

LEPR gene

Polymorphism 1968 G/C

Genotype G/C + C/C

1.3 (0.6–2.5); 0.5

0.7 (0.3–1.8); 0.5

0.8 (0.4–1.8); 0.6

0.8 (0.4–1.4); 0.4

0.8 (0.4–1.5); 0.5

Interaction G/C + C/C – SFA (≥12 g/d)

2.2 (0.9–5.3); 0.07

0.5 (0.1–1.9); 0.3

0.9 (0.4–2.4); 0.9

1.2 (0.5–2.7); 0.6

0.7 (0.3–1.7); 0.5

Interaction G/C + C/C – Total fat (≥83 g/d)

2.5 (1.0–6.2); 0.05

0.9 (0.3–2.8); 0.8

0.8 (0.3–2.2); 0.7

1.6 (0.7–3.7); 0.3

0.6 (0.2–1.3); 0.2

Polymorphism 668 A/G

Genotype A/G + G/G

1.1 (0.6–2.1); 0.7

9.4 (2.1–41.5); 0.003

1.8 (0.8–3.9); 0.2

1.5 (0.8–2.8); 0.2

0.9 (0.5–1.7); 0.7

Interaction A/G + G/G – SFA (≥12 g/d)

2.9 (1.5–5.8); 0.002

3.8 (1.6–8.5); 0.002

2.4 (1.2–4.9); 0.02

1.9 (1.0–3.6); 0.05

1.3 (0.7–2.4); 0.4

Interaction A/G + G/G – Total fat (≥83 g/d)

3.0 (1.5–6.2); 0.002

4.1 (1.8–9.6); 0.001

1.6 (0.8–3.4); 0.2

1.6 (0.8–3.2); 0.14

1.3 (0.7–2.5); 0.4

APOA2 gene

Polymorphism −265 T/C

Genotype T/C + C/C

0.7 (0.4–1.4); 0.3

0.9 (0.4–2.4); 0.9

0.5 (0.2–1.2); 0.1

0.8 (0.4–1.5); 0.5

1.0 (0.5–1.9); 0.9

Interaction T/C + C/C – SFA (≥12 g/d)

2.2 (0.8–5.6); 0.1

1.2 (0.4–3.9); 0.7

0.4 (0.1–1.6); 0.2

1.6 (0.6–3.9); 0.3

1.4 (0.6–1.2); 0.4

Interaction T/C + C/C – Total fat (≥83 g/d)

1.3 (0.6–3.1); 0.5

0.6 (0.2–2.2); 0.5

0.3 (0.08–1.1); 0.07

0.6 (0.3–1.4); 0.3

1.4 (0.6–3.1); 0.4

  1. OR odds ratio, CI confidence interval, SFA saturated fatty acids; Reference category is genotype with major and/or minor frequency with low intake total fat and/or SFA, SFA saturated fatty acids, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol
  2. aOR adjusted by sex, age and physical activity
Back to article page

Lipids in Health and Disease

ISSN: 1476-511X